40673 |
Oncology |
High concordance of actionable genomic alterations identified between ... |
CANCER 2021 10.1002/cncr.33571 |
안명주 |
2021 |
40672 |
Oncology; Respiratory System |
A Response to the Letter to the Editor: Osimertinib Leads the Way Towa... |
J THORAC ONCOL 2021 10.1016/j.jtho.2020.12.009 |
안명주 |
2021 |
40671 |
Oncology |
Global longitudinal assessment of treatment outcomes in recurrent/meta... |
FUTURE ONCOL 2021 10.2217/fon-2020-1087 |
안명주 |
2021 |
40670 |
Oncology |
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib ... |
J CLIN ONCOL 2021 10.1200/JCO.20.03025 |
안명주 |
2021 |
40669 |
Oncology |
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1... |
ANN ONCOL 2021 10.1016/j.annonc.2020.11.020 |
안명주 |
2021 |
40668 |
Oncology; Respiratory System |
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the ... |
J THORAC ONCOL 2021 10.1016/j.jtho.2020.12.002 |
안명주 |
2021 |
40667 |
Oncology |
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-... |
J CANCER RES CLIN 2021 10.1007/s00432-021-03527-4 |
안명주 |
2021 |
40666 |
Oncology |
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Hea... |
J NATL CANCER I 2021 10.1093/jnci/djaa063 |
안명주 |
2021 |
40665 |
Oncology |
Patient-reported outcomes from STARTRK-2: a global phase II basket stu... |
ESMO OPEN 2021 10.1016/j.esmoop.2021.100113 |
안명주 |
2021 |
40664 |
Medicine, General & Internal |
Induction chemotherapy followed by concurrent chemoradiotherapy versus... |
KOREAN J INTERN MED 2021 10.3904/kjim.2019.161 |
안명주 |
2021 |